TNP-2092
- Generic Name
- TNP-2092
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C65H81FN6O15
- CAS Number
- 922717-97-3
- Unique Ingredient Identifier
- W2P7EF7O6O
- Background
TNP-2092 is under investigation in clinical trial NCT03964493 (TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1, Single-center, Double-blind, Placebo-controlled Study of TNP-2092 Capsules, and the Food Effect Study After Single-dose Oral Administration of TNP-2092 Capsules
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- TenNor Therapeutics (Suzhou) Limited
- Target Recruit Count
- 58
- Registration Number
- NCT06178718
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- TenNor Therapeutics Limited
- Target Recruit Count
- 13
- Registration Number
- NCT04294862
- Locations
- 🇺🇸
Rothman Orthopedic Institute, Philadelphia, Pennsylvania, United States
TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- TenNor Therapeutics Limited
- Target Recruit Count
- 120
- Registration Number
- NCT03964493
- Locations
- 🇺🇸
eStudy Site, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath